A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects-Reference-Cited by-同舟云学术

A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects

Published:2015-03-23 Issue:4 Volume:79 Page:650-659
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Zheng Li¹,Li Mao Ping²,Gou Zhong Ping¹,Wang Ying¹,Xu Nan¹,Cai Yong Ming³,Luo Hua⁴

Affiliation:

1. Institute of Clinical Pharmacology/GCP Center; West China Hospital of Sichuan University; Chengdu 610041 China

2. The First Affiliated Hospital of Chongqing Medical University; Chongqing 400010 China

3. Tianjin Institute of Pharmaceutical Research; Tianjin 300193 China

4. Chongqing Fagen Biomedical Inc.; Chongqing 400010 China

Funder

ministry of Science and Technology of China funds

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12528/fullpdf

Reference27 articles.

1. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors;Fattovich;J Hepatol,2008

2. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B;Kim;Antivir Ther,2011

3. How cells respond to interferons;Stark;Annu Rev Biochem,1998

4. Interferons. Signaling, antiviral and viral evasion;Bonjardim;Immunol Lett,2009

5. Interferon alfacon-1 a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C;Melian;Drugs,2001

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality;Blood;2021-04-22

2. Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration;Clinical Drug Investigation;2021-03-16

3. Drug repurposing approach to fight COVID-19;Pharmacological Reports;2020-09-05

4. Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents;Clinical Pharmacokinetics;2020-07-28

5. Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab;Blood;2019-09-05